Dean Karalis

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Karalis DG. Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease. Curr Opin Lipidol. 2023 Aug 21. PMID: 37594008.
      Citations:    
    2. Clegg K, Schubert TJ, Block RC, Burke F, Desai NR, Greenfield R, Karalis D, Kris-Etherton PM, McNeal CJ, Nahrwold R, Pe?a JM, Plakogiannis R, Wong ND, Jones LK. Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study. J Clin Lipidol. 2023 Aug 02. PMID: 37550150.
      Citations:    
    3. Karalis DG, Moeller P, Crawford A, Janelli M, Hessen SE. Impact of the COVID-19 pandemic on the management of risk factors in patients with stable atherosclerotic vascular disease. Am J Prev Cardiol. 2023 Jun; 14:100499. PMID: 37193063.
      Citations:    
    4. Mszar R, Bart S, Sakers A, Soffer D, Karalis DG. Current and Emerging Therapies for Atherosclerotic Cardiovascular Disease Risk Reduction in Hypertriglyceridemia. J Clin Med. 2023 Feb 09; 12(4). PMID: 36835917.
      Citations:    
    5. Schubert TJ, Clegg K, Karalis D, Desai NR, Marrs JC, McNeal C, Mintz GL, Romagnoli KM, Jones LK. Impact of telehealth on the current and future practice of lipidology: a scoping review. J Clin Lipidol. 2023 Jan-Feb; 17(1):40-54. PMID: 36577629.
      Citations:    
    6. Desai NR, Farbaniec M, Karalis DG. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease. Clin Cardiol. 2023 Jan; 46(1):13-21. PMID: 36267039.
      Citations:    
    7. Block RC, Bang M, Peterson A, Wong ND, Karalis DG. Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) - Results of a US national survey. J Clin Lipidol. 2021 Sep-Oct; 15(5):682-689. PMID: 34593357.
      Citations:    
    8. Smith A, Johnson D, Banks J, Keith SW, Karalis DG. Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease. J Clin Med. 2021 Aug 26; 10(17). PMID: 34501275.
      Citations:    
    9. Peterson AL, Bang M, Block RC, Wong ND, Karalis DG. Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia. J Clin Med. 2021 Jul 13; 10(14). PMID: 34300259.
      Citations:    
    10. Wong ND, Bang M, Block RC, Peterson ALH, Karalis DG. Perceptions and Barriers on the Use of Proprotein Subtilisin/Kexin Type 9 Inhibitors in Heterozygous Familial Hypercholesterolemia (From a Survey of Primary Care Physicians and Cardiologists). Am J Cardiol. 2021 08 01; 152:57-62. PMID: 34147211.
      Citations:    
    11. Gianos E, Karalis DG, Gaballa D, Paparodis R, Mintz GL, Balakrishnan M, Myerson M, Brinton EA, Wild RA. Managing cardiometabolic risk factors across a woman's lifespan: A lipidologist's perspective. J Clin Lipidol. 2021 May-Jun; 15(3):423-430. PMID: 33836983.
      Citations:    
    12. Hemphill L, Goldberg A, Hovingh K, Cohen J, Karalis DG. Correction to: Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association. J Gen Intern Med. 2020 Oct 27. PMID: 33111245.
      Citations:    
    13. Karalis DG. Editorial commentary: Advances in the management of dyslipidemia: The future is bright, but what we do today is what matters most. Trends Cardiovasc Med. 2021 10; 31(7):425-426. PMID: 32898691.
      Citations:    
    14. Karalis DG. Are statins safe in patients with COVID-19? J Clin Lipidol. 2020 Jul - Aug; 14(4):396-397. PMID: 32682805.
      Citations:    
    15. Romanelli RJ, Ito MK, Karalis DG, Huang HC, Iorga SR, Kam IW, Thompson S, Azar KMJ. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002-2016. J Clin Lipidol. 2020 May - Jun; 14(3):305-314. PMID: 32362513.
      Citations:    
    16. Hemphill L, Goldberg A, Hovingh K, Cohen J, Karalis DG. Recognition and Treatment of Homozygous Familial Hypercholesterolemia by Primary Care Physicians: a Survey from the National Lipid Association. J Gen Intern Med. 2020 07; 35(7):2225-2227. PMID: 31950403.
      Citations:    
    17. Friedrich DA, Karalis DG, Aspry KE, Martin SS, Guyton JR. JCL roundtable: Lipid treatment targets. J Clin Lipidol. 2019 Mar - Apr; 13(2):223-230. PMID: 31047100.
      Citations:    
    18. Karalis DG, Mallya UG, Ghannam AF, Elassal J, Gupta R, Boklage SH. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 2018 05 15; 121(10):1155-1161. PMID: 29548678.
      Citations:    
    19. Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017 Jul - Aug; 11(4):891-900. PMID: 28550993.
      Citations:    
    20. Karalis DG. A Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids. Adv Ther. 2017 02; 34(2):300-323. PMID: 27981496.
      Citations:    
    21. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol. 2016 Sep-Oct; 10(5):1081-90. PMID: 27678424.
      Citations:    
    22. Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, Cohen JD. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016 Jul-Aug; 10(4):833-841. PMID: 27578114.
      Citations:    
    23. Karalis DG. Achieving optimal lipid goals in the metabolic syndrome: a global health problem. Atherosclerosis. 2014 Nov; 237(1):191-3. PMID: 25240624.
      Citations:    
    24. Victor BM, Teal V, Ahedor L, Karalis DG. Gender differences in achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2014 May 15; 113(10):1611-5. PMID: 24698458.
      Citations:    
    25. Cohen JD, Aspry KE, Brown AS, Foody JM, Furman R, Jacobson TA, Karalis DG, Kris-Etherton PM, Laforge R, O'Toole MF, Scott RD, Underberg JA, Valuck TB, Willard KE, Ziajka PE, Ito MK. Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: proceedings from a workshop. J Clin Lipidol. 2013 Nov-Dec; 7(6):573-609. PMID: 24314357.
      Citations:    
    26. Aspry KE, Furman R, Karalis DG, Jacobson TA, Zhang AM, Liptak GS, Cohen JD. Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. J Clin Lipidol. 2013 Nov-Dec; 7(6):546-60. PMID: 24314354.
      Citations:    
    27. Kimmig LM, Karalis DG. Do omega-3 polyunsaturated Fatty acids prevent cardiovascular disease? A review of the randomized clinical trials. Lipid Insights. 2013; 6:13-20. PMID: 25278765.
      Citations:    
    28. Karalis DG, Victor B, Ahedor L, Liu L. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol. 2012; 2012:861924. PMID: 22888414.
      Citations:    
    29. Smith JA, Karalis DG, Rosso AL, Grothusen JR, Hessen SE, Schwartzman RJ. Syncope in complex regional pain syndrome. Clin Cardiol. 2011 Apr; 34(4):222-5. PMID: 21462216.
      Citations:    
    30. Karalis DG, Subramanya RD, Hessen SE, Liu L, Victor MF. Achieving optimal lipid goals in patients with coronary artery disease. Am J Cardiol. 2011 Mar 15; 107(6):886-90. PMID: 21247526.
      Citations:    
    31. Watson PD, Joy PS, Nkonde C, Hessen SE, Karalis DG. Comparison of bleeding complications with omega-3 fatty acids + aspirin + clopidogrel--versus--aspirin + clopidogrel in patients with cardiovascular disease. Am J Cardiol. 2009 Oct 15; 104(8):1052-4. PMID: 19801023.
      Citations:    
    32. Karalis DG. Intensive lowering of low-density lipoprotein cholesterol levels for primary prevention of coronary artery disease. Mayo Clin Proc. 2009 Apr; 84(4):345-52. PMID: 19339653.
      Citations:    
    33. Sailam V, Karalis DG, Agarwal A, Alani F, Galardi S, Covalesky V, Athanassious C. Prevalence of emerging cardiovascular risk factors in younger individuals with a family history of premature coronary heart disease and low Framingham risk score. Clin Cardiol. 2008 Nov; 31(11):542-5. PMID: 19006117.
      Citations:    
    34. Karalis DG. The role of lipid-lowering therapy in preventing coronary heart disease in patients with type 2 diabetes. Clin Cardiol. 2008 Jun; 31(6):241-8. PMID: 17847038.
      Citations:    
    35. Ford GA, Choy AM, Deedwania P, Karalis DG, Lindholm CJ, Pluta W, Frison L, Olsson SB. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials. Stroke. 2007 Nov; 38(11):2965-71. PMID: 17885258.
      Citations:    
    36. Karalis DG, Ishisaka DY, Luo D, Ntanios F, Wun CC. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol. 2007 Aug 01; 100(3):445-9. PMID: 17659926.
      Citations:    
    37. Karalis DG. The role of advanced lipid testing in clinical practice. Prev Cardiol. 2007; 10(4):228-34. PMID: 17917521.
      Citations:    
    38. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J. 2005 Jan; 149(1):e1. PMID: 15660024.
      Citations:    
    39. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002 Mar 15; 89(6):667-71. PMID: 11897207.
      Citations:    
    Karalis's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (140)
    Explore
    _
    Co-Authors (4)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _